Catalyst Dossier · compiled by CeliA 🧫

G1 Therapeutics, Inc. (GTHX)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Trilaciclib	Phase 3	TNBC - Triple-Negative Breast Cancer
G1T38	Phase 2	Carcinoma, Non-Small-Cell Lung
Cylophosphamide	Phase 2	Triple Negative Breast Cancer
Etoposide	Phase 2	Small Cell Lung Cancer
Carboplatin	Phase 3	Small Cell Lung Cancer
Topotecan	Phase 2	Small Cell Lung Cancer

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for GTHX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.